US FDA’s Two-Month Safety Window For COVID Vaccines Based On Adverse Events In Other Products

 
• By Sue Sutter and Bridget Silverman
Moncef Slaoui at White House press briefing
Moncef Slaoui speaks at a White House press briefing earlier this year.

More from Legislation

More from Pink Sheet